Moving forward, she said, “continued research is needed to learn how to incorporate predictive molecular profiles to optimize treatment selection.”
Dr. Henry reported no relevant disclosures.
Conference Coverage
In Bladder Cancer, New Systemic Treatments Arise
Clinical Topics
-
Despite benefits, extended-interval pembro uptake remains low -
Post Pandemic Return to Colorectal Cancer Screening -
Financial Toxicity in Colorectal Cancer Patient Who Received Localized Treatment in the Veterans Affairs Health System -
Identification of Clinically Actionable Genomic Alterations in Colorectal Cancer Patients From the VA National Precision Oncology Program (NPOP) -
Evaluation of the Prostate Cancer Molecular Testing Pathway (PCMTP) Within the Veterans Health Administration (VHA)
Digital Edition
Multimedia
Conference Coverage
-
Young People’s Gut Bacteria May Drive Colorectal Cancer Risk -
Late-Night Eaters May Have Increased Risk for Colorectal Cancer -
Can Rectal Cancer Patients Benefit from Deintensification of Treatment? -
-
Targeted Colorectal Cancer Combo Improves QoL -
Immunotherapy Combo Wins Big on PFS in First-Line Mets CRC -
Gut microbiome variations may be predictive of precancerous colonic lesions, CRC -
Two multitarget stool tests show promise for CRC screening: Studies -
-
Chemotherapy/local excision avoids proctectomy in rectal cancer
Question 1 of 5
